Lou Hawthorne is the founder and CEO of NaNotics LLC, and the inventor of the company’s platform technology, a programmable subtractive nanoparticle called a NaNot – now the subject of eighteen granted patents. NaNots have already demonstrated efficacy in a mouse model of triple negative breast cancer and are being developed for use in many other diseases. Lou is a scientist–entrepreneur with 25 years experience in founding and leading companies developing new technologies in life science and information technology, including reproductive cloning, human IVF, artificial intelligence and most recently oncology and nanomedicine. In 2002, Lou founded the cloning companies Genetic Savings & Clone and BioArts International, and co-founded Viagen, Inc. acquired by Intrexon (XON) in 2014. Lou graduated in 1983 from Princeton University, where he was a University Scholar and won the Ward Mathis Prize.